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Genomic aberrations involving ETV6 on band 12p13 are amongst the most common chromosomal
abnormalities in human leukemia. The translocation t(6;12)(q23;13) in a childhood B-cell acute
lymphoblastic leukemia (ALL) cell line fuses ETV6 with the putative long non-coding RNA gene STL.
Linking STL properties to leukemia has so far been difficult. Here, we describe a novel gene, OSTL
(annotated as RNF217 in Genbank), which shares the first exon and a CpG island with STL but is transcribed
in the opposite direction. Human RNF217 codes for a highly conserved RING finger protein and is mainly
expressed in testis and skeletal muscle with different splice variants. RNF217 shows regulated splicing in B
cell development, and is expressed in a number of human B cell leukemia cell lines, primary human chronic
myeloid leukemia, acute myeloid leukemia with normal karyotype and acute T-ALL samples. Using a yeast
two-hybrid screen, we identified the anti-apoptotic protein HAX1 to interact with RNF217. This interaction
could be mapped to the C-terminal RING finger motif of RNF217. We propose that some of the recurring
aberrations involving 6q might deregulate the expression of RNF217 and result in imbalanced apoptosis
signalling via HAX1, promoting leukemia development.
R
ecurrent chromosomal translocations are commonly found in human leukemia and constitute the molecu-
lar basis for many hematopoietic malignancies1–3. Leukemic transformation by such aberrations is mainly
driven by either the formation of fusion proteins with novel characteristics or by the deregulation of
oncogene expression4–6. Genomic aberrations involving the gene E-Twenty-Six (ETS) Variant 6 (ETV6) gene
on band 12p13 are amongst the most common chromosomal abnormalities observed in human leukemia. The
ETS domain transcription factor ETV6 can be fused to more than 30 different partners, including protein tyrosine
kinases as PDGFRB, ABL1 and 2, and JAK2, and a number of transcription factors including RUNX17–9.
In 1997, we identified a novel fusion partner of ETV6, which we named Six-Twelve-Leukemia (STL) gene10. STL
was cloned from the childhood B-cell ALL cell line SUP-B2 (ref. 11) that has a t(6;12)(q23;p13) translocation and
a deletion of the 12p13 region of the normal chromosome 12 and therefore lacks wildtype ETV6 (ref. 12). The
current annotation localizes STL to 6q22.31. Whereas 6;12 translocations by themselves are recurrent but quite
rare12,13, 6q is a genomic region frequently deleted in lymphoblastic leukemia and lymphomas13–15. The STL
sequence does not contain any long open reading frames, and if the reading frame of ETV6 is continued into STL
in the ETV6/STL fusion transcript, a stop codon is encountered after 14 amino acids10. It has been difficult to
propose a mechanism by which the ETV6/STL fusion might drive leukemogenic transformation as no apparent
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Here, we describe a novel gene, opposite STL (OSTL), which shares
the first exon and a CpG island with the putative long non-coding
(nc)RNA gene STL but is transcribed in the opposite direction.
RNF217 codes for a 284 amino acid protein with two RING finger
domains linked by an in-between-RING fingers (IBR) motif. The
RNF217 protein is highly conserved across species and is expressed
in various tissues. RNF217 expression can be detected in a number of
human leukemia cell lines and it is overexpressed in myeloid leuke-
mia patient samples. Using a yeast two-hybrid screen, we demon-
strated the RNF217 protein to interact with HAX1, a protein
involved in apoptotic signaling. We propose that the leukemogenic
properties of the ETV6/STL fusion may not arise from a fusion
protein but rather from the disruption or the transcriptional dereg-
ulation of the STL/RNF217 locus. The high expression of RNF217 in
certain human leukemias suggests that the deregulation of this gene
could be a more common mechanism in leukemogenesis.
Results
Genomic organization of the STL/RNF217 locus. We have
previously identified the t(6;12)(q23;p13) ETV6/STL fusion
(Figure 1a) as a potentially recurrent genomic rearrangement in
human leukemia10. As STL itself has no apparent open reading
frame and in the ETV6/STL fusion transcript the STL portion only
extends the ETV6 open reading frame by 14 amino acids, we assessed
the genomic locus around the STL gene in order to find genes near
the breakpoint that might possibly be deregulated due to the genomic
rearrangement. Doing so, we identified Opposite of STL (OSTL, also
annotated as ring finger protein, RNF217, or in-between-RING
finger domain-containing IBRDC1) sharing the first exon with
STL, but being transcribed in the opposite direction (Figure 1b).
The STL gene in Figure 1b (sequence in Supplementary Figure S1)
is derived from our previous study10 and differs from the UCSC
annotation (uc003pzq.3) in its centromeric, 39 portion. The human
STL/RNF217 genomic locus spans more than 450 kbp on 6q22.31.
STL is also annotated as RNF217-AS1 in the genenames.org database,
indicating that STL could act as an antisense transcript for RNF217.
Nevertheless, it has to be kept in mind that STL only overlaps with the
first exon of RNF217. The RNF217 gene is composed of 13 exons
(Figure 1c, Supplementary Table S1). In the human RNF217 cDNA
sequence (Ensembl RNF217-202, Transcript ID ENST00000560949,
Supplementary Figure S2), the second start codon (ATG, under-
lined) probably represents the true translational start site, because
it is embedded in a better Kozak consensus sequence and it is
homologous to the ATG in mouse Rnf217 (Supplementary Figure
S3). Both start codons are located within the first exon of the RNF217
gene, which is associated with a CpG island. The RNF217 transcript is
subject to extensive alternative splicing. We identified at least 7
putative protein encoding splice variants of RNF217 (Supplemen-
tary Table S2).
RNF217 is a highly conserved member of the RING finger family
of proteins. The open reading frame of the human RNF217 encodes a
284 amino acid protein (when using the second ATG as the start
codon) with a calculated molecular mass of 30 kDa (Figure 2a). A
database search against the RNF217 protein sequence identified
three domains, a variant N terminal RING finger (RING1), an
IBR, also known as double RING finger linked motif (DRIL), and a
consensus RING finger (RING2) at the C terminal end. Comparison
between the consensus sequence and the RNF217 RING motifs
revealed the RNF217 RING1 to have a lysine residue rather than a
histidine residue at the H4 position. The spacing between cysteins 7
and 8 in RING1 is 4 amino acids in RNF217 compared to 2 amino
acids in the consensus (Figure 2a). RNF217 is highly conserved
across species. Sequence comparison revealed 98.6% amino acid
identity between human and mouse RNF217, 76.8% between
Figure 1 | Genomic organization of the ETV6/STL fusion and the STL/RNF217 locus. (a) The t(6;12)(q23;13) genomic rearrangement. (b) RNF217
shares the first exon with STL but is transcribed in the opposite direction. (c) Exon-intron organization of the RNF217 gene with two possible splice
variants.
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human and Fugu rubripes (puffer fish) Rnf217, and 79.6% between
human and Danio rerio (zebrafish) Rnf217 (Figure 2b).
Tissue-specific expression of RNF217. We analyzed the expression
of RNF217 in various human tissues using a human multiple tissue
Northern blot (Figure 3a). RNF217 transcripts of 9.5 and 4.4 kbp
were detected in a number of tissues. The strongest expression was
detected in testis (with an additional transcript of 1.35 kbp) and in
skeletal muscle (with an additional transcript of 2.4 kbp). Weaker
expression was detected in prostate, ovary, heart, placenta, liver, and
pancreas.
Expression of RNF217 in human B cell leukemia cell lines and B
cell developmental stages. We hypothesized that the tissue-
restricted expression of RNF217 might be deregulated in human B
cell leukemia10,13–14. To test this, we analyzed the mRNA expression of
this gene in a number of human leukemia cell lines by RT-PCR
(Figure 3b). A 160 bp fragment was amplified in the mature B cell
NHL cell line Granta 519 (ref. 16), two Eppstein Barr virus
transformed lymphoblastoid cell lines (LCL B and LCL D) and in
the precursor B-cell ALL cell line SEM17. The expression of RNF217
does not correlate with reported deletions of 12p13 or the STL/
RNF217 locus in these cell lines. Next, we assessed different B cell
Figure 2 | RNF217 is a highly conserved member of the RING finger family of proteins. (a) Diagram of the RNF217 protein with its functional
domains annotated. Comparison of the RNF217 protein domains to the consensus sequences. (b) Protein sequence comparison of the human, mouse,
Fugu, and zebrafish RNF217 proteins.
www.nature.com/scientificreports
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developmental stages for their expression of RNF217 (Figure 3c).
Distinct transcripts of various sizes could be amplified from all
developmental stages indicating tightly regulated alternative
splicing of RNF217 over the course of B cell development. The
SEM cell line was used as a positive control for RNF217 expression.
RNF217 expression in primary bone marrow samples from
human leukemia patients. To further assess the potential
contribution of RNF217 to human leukemia, we analyzed primary
bone marrow samples derived from leukemia patients (Figure 4a).
RNF217 was expressed in normal bone marrow and expression levels
varied among both AML and ALL samples. We analyzed microarray
data from 129 leukemia patient and 10 normal bone marrow samples
to quantitatively assess RNF217 expression levels across 12 different
leukemia types in comparison to normal bone marrow cells. This
screening revealed CML samples to have the highest relative
expression levels of RNF217 (Figure 4b). Quantitative RT-PCR
analysis of 19 ALL and 20 myeloid leukemia samples (10 CML and
10 AML samples with normal karyotype) proved myeloid leukemia
samples to have an overall higher expression of RNF217 compared to
lymphoblastic leukemia samples (AML vs. ALL P50.0096; CML vs.
ALL P50.0006) with the AML samples having slightly higher
expression levels than the CML samples (Figure 4c).
Identification of RNF217 interacting proteins. The STL/RNF217
genomic locus at 6q22.31 is close to frequent targets of genomic
aberrations12–15 and RNF217 is highly expressed in human myeloid
leukemias when compared to normal bone marrow. We therefore
assumed that the deregulation of RNF217 might be a potential driver
of human leukemogenesis and were interested in mechanisms of how
RNF217 might promote leukemia. To this end, we performed a yeast
two-hybrid protein interaction screen to identify interaction partners
of RNF217. The RNF217 protein served as bait to screen a Hela S3
cDNA prey library. Of 24 prey clones that were identified in the
Figure 3 | Expression of RNF217 in human tissues and B cells. (a) Multiple human tissue northern blot hybridized with a radioactively labeled RNF217
probe. (b) Cell lines derived from human B cell neoplasms were analyzed for their expression of RNF217 by RT-PCR. TBP expression was assessed as a
control. The primers that were used for this experiment covered exons 9 and 11 of the RNF217 gene (see Supplementary table 1), to allow for the detection
of all putative protein-coding splice variants shown in Supplementary table 2. Note that the RNF217 gel picture is a composite of two different gels.
(c) Determination of RNF217 expression and splicing during B cell development. GAPDH expression was assayed as control.
www.nature.com/scientificreports
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screen, 8 contained either the full-length open reading frame of HS1-
associated protein X-1 (HAX1) or parts of it (Figure 5).
Mapping of the RNF217 interaction domain with HAX1. To
define which region of the RNF217 protein mediates the
interaction with HAX1, several deletion mutants were constructed
and assayed by using the two-hybrid system (Figure 6a and b).
Colonies could only grow if the RING1 domain of RNF217 was
present, demonstrating the necessity for this domain in the
protein-protein interaction with HAX1. The physical interaction
between RNF217 and HAX1 was further confirmed by co-
immunoprecipitation of in vitro translated myc- and HA-tagged
RNF217 and HAX1 proteins, respectively, (Figure 6c) and after co-
transfecting CFP-RNF217 and YFP-HAX1 into HEK293T cells
(Figure 6d). Finally, immunofluorescence microscopy of NIH3T3
mouse fibroblast cells co-transfected with CFP-RNF217 and YFP-
HAX1 revealed cytoplasmic co-localization of the two proteins
(Figure 6e).
Discussion
Chromosomal rearrangements, especially balanced chromosomal
translocations are common events in human leukemia. Many fusion
proteins and gene deregulations resulting from these translocations
are active drivers of leukemogenesis with known transformational
mechanisms1–5,18–21. Apart from obviously functional fusions, it is of
utter clinical importance to understand the leukemogenic mechan-
Figure 4 | Expression of RNF217 in primary human leukemia samples. (a) Primary human bone marrow samples from leukemia patients were analyzed
for their expression of RNF217 by RT-PCR. TBP expression was assayed as a control. (b) Microarray expression profiles of primary human bone marrow
samples from leukemia patients19 were generated. Data for RNF217 expression was log2 transformed and evaluated (normal bone marrow (nBM; n510),
CML; n510, CALM/AF10-positive AML (CALM_AF10; n510), AML with normal karyotype and FLT3 negative (AML_nk; n510), AML with MLL
rearrangement (AML_MLL; n59), AML with inv(16)(p13q22) (CBFB-MYH11 fusion, AML_M4; n510), AML with t(15;17)(q21;q22) (PML-RARA
fusion, AML_M3; n510), AML with t(8;21)(q22;q22) (AML1-ETO fusion, AML_M2; n510), AML with normal karyotype and FLT3-ITD (AML_FLT3;
n510), AML with complex aberrant karyotype (AML_comp; n510), ALL with t(9;22)(q34;q11) (BCR-ABL fusion, ALL_Ph; n510), ALL with
t(4;11)(q21;q23) rearrangement (MLL-AF4 fusion, ALL_MLL; n510), common ALL (ALL_BA; n510), and pro-B ALL (ALL; n510)). The probe set for
RNF217 on the microarrays used (Affymetrix HGU133, probe set 235492_AT) detects exon 13 of human RNF217 (see Supplementary table 1). This exon
is part of all splice variants shown in Supplementary table 2. (c) RNF217 expression in primary human bone marrow samples from leukemia patients was
assessed by quantitative RT-PCR with b-actin as reference gene. Expression levels were calculated from cT values by the 2
-Dc
T method (ALL; n519, AML;
n510, CML; n510), Mean 6 standard error of mean. ** P # 0.01. The primers used for this experiment span exons 11 and 12 of the human RNF217 gene
(see Supplementary table 1). It has to be noted that not all of the identified putatively protein-coding splice variants of RNF217 contain exon 12 (see
Supplementary table 2), therefore it is possible that not all splice variants of this gene in the leukemic samples might have been detected.
www.nature.com/scientificreports
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isms of recurrent genomic rearrangements that do not result in
apparent fusion proteins or in the obvious transcriptional regulation
of breakpoint adjacent genes.
We previously described a fusion between ETV6 on chromosome
12 band p13, and STL on 6q23 (ref. 10). The functional consequences
of the ETV6/STL fusion transcript are difficult to interpret as STL
does not contain an obvious open-reading frame, and the STL por-
tion in the ETV6/STL fusion only adds a short 14 amino acid tail to
the first 54 amino acids of the ETV6 protein10. An alternative
explanation for recurrent 6;12 translocations12,13 and frequent dele-
tions on 6q13–15 could be the deregulation of a gene close to the break-
points of these rearrangements.
We analyzed the STL genomic locus and identified a novel gene,
OSTL (probable E3 ubiquitin protein ligase RNF217), which shares
the first exon and a CpG island with the putative long ncRNA STL
but is transcribed from the opposite DNA strand in the opposite
direction. The protein encoded by RNF217 is highly conserved in
evolution in vertebrates and harbors important protein domains
(RING domains), putatively involved in the ubiquitination of pro-
teins22. Deregulated ubiquitination has wide implications in human
leukemia23–26 and the successful introduction of proteasome inhibi-
tors for the treatment of multiple myeloma proved that the ubiqui-
tin-proteasome system is a valid therapeutic target in leukemia
including AML27–29.
We demonstrated RNF217 to be expressed mainly in testes and
skeletal muscle. Interestingly, the expression pattern of RNF217
resembles that of STL10, indicating co-regulation of the two genes.
This assumption is further strengthened by the fact that exon 1,
which is shared by STL and RNF217, is associated with the only
CpG island found in the entire STL/RNF217 locus, which spans close
to 450 kbp (chr6:124,976,000–125,414,000, hg19). Tagawa and col-
leagues described genomic rearrangements at 6q21-22 in two T-cell
lymphoma cell lines, which affected the gene adjacent to the RNF217
gene towards the centromer (NKAIN2, TCBA1). One of the break-
points described by Tagawa and colleagues was within the STL
locus, supporting a possible involvement of the STL/RNF217 locus
in lymphomagenesis30.
Human B cell leukemia cell lines and primary bone marrow sam-
ples from leukemic patients expressed RNF217 to varying levels.
Quantitative expression analysis by both RT-PCR and microarrays
revealed patients with chronic myeloid leukemia and acute myeloid
leukemia with a normal karyotype to have the highest levels of
RNF217 expression among our cohort. Even though the ETV6/STL
fusion was initially cloned from a B cell acute lymphoblastic leukemia
cell line, the expression levels of RNF217 were highest in myeloid
leukemia patient samples in our study. Publicly available data shows
varying expression of RNF217 in the human hematopoietic compart-
ment and in hematopoietic malignancies with myeloid leukemia
showing considerably higher expression of RNF217 than lymphoid
leukemias (ist.mediasapiens.com, Supplementary Figure S4).
Although RNF217 is not recurrently mutated in hematologic malig-
nancies (0.18% mutation frequency), it is a frequent target for copy
number alterations in solid tumors as summarized in the Catalogue
of somatic mutations in cancer (COSMIC) database.
Gorbea and colleagues identified RNF217 as an interaction part-
ner of the 26 S proteasome-binding protein ECM26 using a genome-
wide two hybrid screen and mass spectrometry31. No other protein-
interactions of RNF217 have been described so far. Performing a
yeast two-hybrid screen and co-immunoprecipitation experiments,
we identified the anti-apoptotic protein HAX1 to interact with
RNF217. This interaction is mediated by the RING1 domain of
RNF217 that is encoded by both exons 1 and 7 (Supplementary
Table S2 and Supplementary Figure S2). It has to be noted that not
all of the splice variants that we could identify in this study contain
exon 7 and therefore it seems plausible that not all RNF217 proteins
are able to interact with HAX1.
HAX1 was initially found as an interaction partner of HS1, an
intracellular protein that mediates signaling triggered by antigen
receptor activation. The 35 kDa HAX1 protein is ubiquitously
expressed32 (see also ist.medisapiens.com, Supplementary Figure
S5) and localizes mainly to mitochondria32. It plays an essential role
in the maintenance of the mitochondrial membrane potential – and
thereby prevents the initiation of the cell intrinsic, mitochondria-
mediated apoptosis pathway33. HAX1 contains two Bcl-2 homology
domains, which indicates its anti-apoptotic function to be related to
BH domain oligomerization. It further harbors a PEST sequence, and
a putative transmembrane domain. The PEST sequence is respons-
ible for HAX-1 being conjugated with K48-linked ubiquitin chains
Figure 5 | Result from the yeast two-hybrid screen. AH109 yeast cells were co-transformed with pGAD-GH prey plasmids containing the human
cDNA Hela S3 library and the pGBKT7-RNF217 bait plasmid. Positive clones were sequenced. Of 24 positive clones, 8 contained either the full-length
open reading frame of HS1-associated protein X-1 (HAX1), or parts of it as shown. * HAX-1 clone 5 was used in the yeast two-hybrid experiments to
confirm interaction with RNF217.
www.nature.com/scientificreports
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and degraded, demonstrating the interplay between polyubiquitina-
tion and apoptosis-inhibition by HAX1 (ref. 34). HAX1 interacts
with several integral parts of the intracellular apoptosis machinery
and can be cleaved by various pro-apoptotic proteases35–37. HAX1
promotes Omi/HrtA2 processing and thereby attenuate apoptosis38,
it prevents the polyubiquitination and subsequent proteasomal
degradation of the anti-apoptotic protein XIAP39, and inhibits cas-
pase 9 activation40. Ectopic expression of HAX1 promotes esopha-
geal squamous carcinoma cell proliferation and chemoresistance in
vitro and increases tumor growth in vivo in a xenograft mouse model,
whereas knock-down of HAX1 has opposite effects41.
HAX1 is highly expressed in human malignancies of mature B
cells (CLL, myeloma, plasma cell leukemia), whereas its expression
is lower in CML and AML42 (see also ist.medisapiens.com,
Supplementary Figure 5). Interestingly, HAX1 may replace BCL-2
when it comes to the necessity for the expression of anti-apoptotic
proteins in lymphomas42. The preferred overexpression in B cell
leukemias might mirror the dependency of normal B cell develop-
ment on HAX1. Indeed, a study employing HAX1 deficient mice
demonstrated severe B cell developmental defects43.
Klein and colleagues found HAX1 deficiency to be the cause for
Kostmann disease, an autosomal recessive primary immunodefi-
ciency syndrome with severe congenital neutropenia (OMIM
610738)33. This disorder is characterized by increased neutrophil
apoptosis and demonstrates HAX1 to be an important player in
myeloid homeostasis. The molecular mechanism appears to be a
defect in G-CSF-triggered granulopoiesis44. Of particular interest is
the fact that patients suffering from Kostmann disease are prone to
myelodysplastic syndrome and AML45.
The fact that one third of the RNF217 interacting prey clones
identified in our yeast two hybrid screen contained HAX1 sequences
suggest that HAX1 is a very prominent interaction partner of
RNF217. Considering the important role of HAX1 in apoptosis
homeostasis and its involvement in the development and malignant
diseases of both the B lymphoid and myeloid lineage argue for an
important role of RNF217 in this context as well. Loss of the STL/
RNF217 locus and subsequent deregulation of HAX1 degradation
might result in shifting apoptotic balance towards cell survival, con-
tributing to malignant transformation and leukemia progression.
The STL/RNF217 locus shows a peculiar organization of an
ncRNA gene (STL) and a very conserved protein-coding gene
(RNF217) sharing a common first exon and a CpG island.
Genomic loci with a similar organization are frequently imprinted
or show allelic exclusion46–48. STL might be a cis-acting antisense
Figure 6 | Confirmation and mapping of the RNF217-HAX1 interaction. (a) and (b) The pGBKT7 plasmid containing RNF217 deletion mutants
and the pGADT7 plasmid containing full-length HAX1 were co-transformed into AH109 yeast cells to map the interaction domains of RNF217.
(c) In vitro translated [35S]-HA-RNF217 and –myc-HAX1 were mixed 151 and immunoprecipitated with an anti-myc antibody. Proteins were separated
by SDS-PAGE and the gel was subjected to autoradiography. (d) pCFP-RNF217 and pYFP-HAX1 were co-transfected into HEK293T cells and the cells
were lysed 24 h later. HAX1 was immunoprecipitated and proteins were separated by SDS-PAGE and CFP-RNF217 was detected using a mouse anti-GFP
antibody. (e) NIH3T3 cells were transiently transfected and grown on cover slips for 12-24 h after transfection. Cells were fixed, mounted on glass slides,
and analyzed using an inverted fluorescence microscope.
www.nature.com/scientificreports
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transcript or alternatively regulate RNF217 by transcriptional inter-
ference. This is emphasized by the alternative annotation of STL as
RNF217-AS1 (genenames.org). Nevertheless, it has to be kept in
mind that STL only overlaps with the first exon of RNF217.
Examples for overlapping cis-acting ncRNAs include the Xist/Tsix
locus that is essential in X chromosome inactivation49, the Kcnq1
locus50, and the IGF2R/AIRN locus51,52. Loci in which both an
ncRNA and an adjacent gene share their respective first exons and
a common GpC island include e.g. the IGF2 gene and its antisense
ncRNA involved in Beckwith-Wiedemann and Russell-Silver syn-
dromes53, and Wilm’s tumor54, the LEF1 gene, which is important in
T cell development55, and the HOXA6/HOXA-AS3 transcript variant
1 locus.
Considering the unusual structure of the STL/RNF217 locus and
the lack of an obvious ETV6/STL fusion protein, a possible mech-
anism for the leukemogenic effect of the t(6;12)(q23;p12) transloca-
tion could be a transcriptional deregulation of the RNF217 gene.
There are at least two mechanism that could lead to RNF217 dereg-
ulation: 1) disruption of the STL gene and subsequent loss of its
putative cis-acting influence on RNF217; 2) an intronic enhancer
from the ETV6 locus might lead to increased expression of
RNF217, a mechanism that has been proposed for several other
ETV6 rearrangments9,56–59.
Deregulated RNF217 expression might cause apoptotic imbalance
due to interference with HAX1 degradation. The strong phenotype
associated with genetic disorders involving HAX1 supports an
important role for HAX1 in human hematopoiesis and leukemogen-
esis33,41–45. On the one hand, RNF217 is highly expressed in some
human leukemias, on the other hand, the STL/RNF217 locus is a
frequent target of gene loss in human B cell neoplasias10,13–15. This
all suggests that the deregulation of this protein should be further
explored as a possible mechanism of leukemogenesis. However, it
needs to be noted that to formally prove a link between RNF217 and
leukemia, animal models overexpressing RNF217 need to be
developed and the molecular functions of RNF217 need to be
studied.
Methods
Patient samples. Bone marrow samples were collected from leukemic patients.
Peripheral blood and bone marrow samples for B cell sorting were collected from
healthy donors. Informed consent was obtained in accordance with the declaration of
Helsinki and local ethical guidelines. RNF217 expression was analyzed in a
microarray dataset published by us in 2012 (ref. 19). For the RT-PCR experiments,
patient samples were obtained from diagnostic leukemia samples acquired from 2000
to 2009 (Laboratory for Leukemia Diagnostics, Department of Medicine III,
Grosshadern, Ludwig Maximilians University, Munich, Germany). The study was
approved by the institutional review board (Ludwig-Maximilians-University [LMU]-
Munich).
Cell lines. BL2, BL4, DOHH2, Granta 519, Karpas 422, NCEB1, and Wsu-NHL cell
lines were provided by Martin Dreyling, Department of Medicine III, Munich,
Germany. LCL B, LCL D, and LCL R cell lines were provided by Martin Schlee, and
the SEM cell line by Georg Bornkamm, both Helmholtz Zentrum Munich, Munich,
Germany.
Plasmid construction. The bait plasmids for the yeast two-hybrid screen were
generated by inserting either the full length RNF217 cDNA or different RNF217
deletion mutants (1. Full-length RNF217 (aa 1-283), 2. aa 35-211, 3. aa 5-87, 4. aa 35-
164, 5. aa 159-283, 6. aa 159-211, 7. aa 194-283, 8. aa 36-211) in frame into the
pGBKT7 vector (Clontech, Heidelberg, Germany) to be expressed as GAL4-DBD
fusion proteins. A commercially available Hela S3 cDNA library cloned into the
pGAD-GH vector to give rise to proteins as GAL4-AD fusions (Clontech) was used as
prey library. To map the RNF217 interaction with HAX1, full-length HAX1 was
cloned into a modified pGADT7 vector. For intracellular localization experiments,
RNF217 and HAX1 were cloned into the vectors pECFP and cEYFP, respectively
(Clontech).
Characterization of the RNF217 gene. The human RNF217 gene was mapped from
the UniGene database clone IMAGp998E064109Q2 (reference AA992964). Sequence
homology was assessed by BLAST and protein domains were identified using
PROSITE pattern search.
Human multiple tissue Northern blot. A human multiple tissue northern blot
(Clontech) was hybridized with a radioactively labeled (Megaprime kit, Amersham
Pharmacia Biotech Freiburg, Germany) 748 bp RNF217 cDNA probe, PCR amplified
from mouse testis cDNA using the primers 59-CTACCTCGAGAGATGAAGGTAC-
AACTTGGCC-39 and 59-CATACTGCAGTGTTACCAGTGCATACCTGTCCG-
39. The blot was subjected to autoradiography, stripped and reprobed for b-actin.
Expression of RNF217 in human B cells/B cell leukemia cell lines and human
leukemia patient bone marrow samples. B cell developmental stages were flow
sorted from bone marrow (BM) and peripheral blood (PB) (pre-B: BM,
CD191VpreB1; B1: PB, CD191CD51; naı̈ve: PB, CD191CD27-; memory: PB,
CD191CD271; plasma cells: PB, CD191CD38brightCD1381) on an Epics Elite cell
sorter (Beckman Coulter, Krefeld, Germany) into RNA later solution (Ambion,
Austin, TX, USA).
Total RNA was extracted using QiaShredder columns and the RNeasy Mini Kit
(both from Qiagen, Hilden, Germany). RNA was reversed transcribed using
Superscript reverse transcriptase (Invitrogen, Darmstadt, Germany) and amplified
with primers as follows: For human B cell leukemia cell lines and primary human
bone marrow/leukemia samples: RNF217 59-AGAGGAATGCCCAGAAGTGTCC-
39 and 59-ACTGAGGTTTGATGTGTGGTCTCC-39, TBP 59-GCACAGGAG-
CCAAGAGTGAA-39 and 59-TCACAGCTCCCCACCATGTT-39. For the human B
cell developmental stages: RNF217 59-GAGTGCCTCAAAGTCTACCTG-39 and 59-
CATACTGCAGTGTTACCAGTGCATACCTGTCCG-39, GAPDH 59-GCACCA-
CCAACTGCTTAGCACC-39 and 59-GTCTGAGTGTGGCAGGGACTC-39. For
quantitative RT-PCR, cDNA derived from primary human leukemia samples was
amplified with the primers RNF217 59-TCCCAGAGAGACCTCATTTAAGGA-39
and 59-CCCTAGTGCCAATCCCAAAA-39 together with the TaqMan (FAM/BHQ-
1) probe 59-CGAGGGTCAGTCTGTGCTGGAAAATTATTCAT-39. The human b-
actin endogenous control (VIC/TAMRA probe) (Life Technologies, Darmstadt,
Germany) was used for normalization. Relative RNF217 expression levels were
determined using the DCT method.
Yeast two-hybrid screen and mapping of RNF217-HAX1 interaction. The yeast
strain AH109 (Clontech) was co-transformed with the pGAD-GH prey plasmid
containing the human cDNA Hela S3 library and the pGBKT7-RNF217 bait plasmid
by lithium acetate transformation. Clones harboring interacting bait/prey proteins
grew in the absence of tryptophan, leucine, histidine, and adenine, and showed X-a-
gal activity. Positive clones were sequenced and annotated. For the mapping of the
interaction between RNF217 and HAX1, RNF217 deletion mutants were cloned into
the pGBKT7 bait plasmid and full-length HAX1 into the pGADT7 plasmid. Both
plasmids were used to cotransform AH109 yeast cells.
Transfection of adherent cells. Cells were transiently transfected using cationic
polymers (RothFect, Carl Roth, Darmstadt, Germany or PolyFect, Qiagen). For
fluorescence microscopy, NIH3T3 cells were grown on cover slips for 12–24 h after
transfection, fixed with formaldehyde, mounted on glass slides, and analyzed using an
inverted fluorescence microscope (Axiovert 200 M, Carl Zeiss, Goettingen,
Germany).
In vitro co-immunoprecipitation of RNF217 and HAX1. Radioactively labeled
[35S]-proteins were produced using the TNT-reticulocyte-lysate system (Promega,
Mannheim, Germany). RNF217 was expressed from the pGBKT7 vector to give rise
to a HA-tagged protein, HAX1 was expressed from the pGADT7 vector to give rise to
a myc-tagged protein. The in vitro translated proteins were mixed 151 and
immunoprecipitated with an anti-HA (RNF217) or an anti-myc antibody (HAX1)
together with protein A beads (Clontech). Proteins were separated by SDS-PAGE, the
gel was fixed and incubated with fluorographic amplification reagent (Amersham)
before being exposed to an X-ray film (Kodak, Stuttgart, Germany).
pCFP-RNF217 and pYFP-HAX1 were co-transfected into HEK293T cells and the
cells were lysed 24 h later. HAX1 was immunoprecipitated with a mouse anti-HAX1
antibody (Clontech) or control polyclonal mouse IgG (Santa Cruz, Heidelberg,
Germany) and protein G-agarose beads (Roche, Mannheim, Germany). Proteins
were separated by SDS-PAGE, blotted on nitrocellulose membranes (BioRad,
Munich, Germany) by semi-dry blotting (BioRad), and CFP-RNF217 was detected
using an mouse anti-GFP antibody (Molecular Probes, Darmstadt, Germany) with an
HRP-conjugated secondary anti-mouse antibody (Santa Cruz) and enhanced
chemiluminescence detection (Amersham).
Statistics. For the statistical analysis of qRT-PCR data (Figure 4c), normality for all
groups was tested for by the Shapiro-Wilk test. ALL and AML samples were identified
to be not normally distributed. Therefore, all groups were compared using the non-
parametric Mann–Whitney U test. Differences with a P-value below 0.01 were seen as
statistically highly significant and marked **.
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